title: Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18-25 years enrolled in a clinical trial.
abstract: Baseline human papillomavirus (HPV) prevalence and type distribution were evaluated in young Chinese women enrolled in a clinical trial of an HPV vaccine (ClinicalTrials.gov registration NCT00779766). Cervical specimens and blood samples were collected at baseline from women aged 18-25 years (n = 6,051) from four sites across Jiangsu province. Cervical specimens were tested for HPV DNA by SPF10 PCR-DEIA-LiPA25 version 1, and HPV-16/18 type-specific polymerase chain reaction. Anti-HPV-16 and anti-HPV-18 antibody titres were quantified by enzyme-linked immunosorbent assay. At baseline, 15.3% of women were DNA positive for any of 14 HPV high-risk (hr) types (HPV-16/18/31/33/35/39/45/51/52/56/58/59/66/68). The most commonly detected hrHPV types in cervical specimens were HPV-52 (4.0%) and HPV-16 (3.7%). High-risk HPV DNA-positivity increased with severity of cytological abnormalities: 39.3% in atypical squamous cells of undetermined significance, 85.0% in low-grade squamous intraepithelial lesions and 97.8% in high-grade squamous intraepithelial lesions (HSIL). The hrHPV types most frequently detected in HSIL were HPV-16 (63.0%), HPV-18 (17.4%), HPV-52 (17.4%), HPV-58 (15.2%) and HPV-33 (15.2%). The hrHPV types most frequently detected in cervical intraepithelial neoplasia 2+ were HPV-16 (66.1%), HPV-33 (16.1%), HPV-52 (16.1%), HPV-58 (14.5%) and HPV-51 (11.3%). Multiple hrHPV infections were reported for 24.4% of hrHPV DNA positive women. Regardless of baseline HPV DNA status, 30.5% and 16.0% of subjects were initially seropositive for anti-HPV-16 and anti-HPV-18, respectively. In conclusion, the high baseline seropositivity rate and intermediate prevalence of cervical hrHPV types in Chinese women aged 18-25 years underlines the importance of early HPV vaccination in this population.
authors.affiliation: Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CICAMS) and Peking Union Medical College, Beijing, China.
authors.forename: Fang-Hui
authors.initials: FH
authors.lastname: Zhao
authors.forename: Feng-Cai
authors.initials: FC
authors.lastname: Zhu
authors.forename: Wen
authors.initials: W
authors.lastname: Chen
authors.forename: Juan
authors.initials: J
authors.lastname: Li
authors.forename: Yue-Mei
authors.initials: YM
authors.lastname: Hu
authors.forename: Ying
authors.initials: Y
authors.lastname: Hong
authors.forename: Yi-Ju
authors.initials: YJ
authors.lastname: Zhang
authors.forename: Qin-Jing
authors.initials: QJ
authors.lastname: Pan
authors.forename: Jia-Hong
authors.initials: JH
authors.lastname: Zhu
authors.forename: Xun
authors.initials: X
authors.lastname: Zhang
authors.forename: Yong
authors.initials: Y
authors.lastname: Chen
authors.forename: Haiwen
authors.initials: H
authors.lastname: Tang
authors.forename: Helen
authors.initials: H
authors.lastname: Zhang
authors.forename: Christelle
authors.initials: C
authors.lastname: Durand
authors.forename: Sanjoy K
authors.initials: SK
authors.lastname: Datta
authors.forename: Frank
authors.initials: F
authors.lastname: Struyf
authors.forename: Dan
authors.initials: D
authors.lastname: Bi
mesh_terms: D000293:Adolescent; D000328:Adult; D002584:Cervix Uteri / Q000473:pathology; D002681:China / Q000453:epidemiology; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004279:DNA, Viral / Q000235:genetics; D004311:Double-Blind Method; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D009367:Neoplasm Staging; D027383:Papillomaviridae / Q000145:classification* / Q000235:genetics / Q000302:isolation & purification; D030361:Papillomavirus Infections / Q000453:epidemiology* / Q000517:prevention & control / Q000821:virology; D053918:Papillomavirus Vaccines / Q000627:therapeutic use; D016133:Polymerase Chain Reaction; D015995:Prevalence; D011379:Prognosis; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D002578:Uterine Cervical Dysplasia / Q000453:epidemiology* / Q000517:prevention & control / Q000821:virology; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology* / Q000517:prevention & control / Q000821:virology; D014626:Vaginal Smears; D016387:Women's Health; D055815:Young Adult
chemical_list: D004279:DNA, Viral; D053918:Papillomavirus Vaccines
keywords: China; human papillomavirus; prevalence; type distribution; women
references.citation: Vaccine. 2008 Aug 19;26 Suppl 12:M30-42
references.pmid: 18945412
references.citation: Lancet Infect Dis. 2007 Jul;7(7):453-9
references.pmid: 17597569
references.citation: J Clin Microbiol. 2006 Sep;44(9):3292-8
references.pmid: 16954263
references.citation: Br J Cancer. 2006 Dec 4;95(11):1593-7
references.pmid: 17088908
references.citation: Int J Cancer. 2012 Nov 15;131(10):2349-59
references.pmid: 22323075
references.citation: Br J Cancer. 2004 Feb 9;90(3):638-45
references.pmid: 14760378
references.citation: Int J Cancer. 2007 Sep 15;121(6):1306-11
references.pmid: 17417776
references.citation: Cancer Epidemiol. 2012 Aug;36(4):384-90
references.pmid: 22377277
references.citation: Int J Cancer. 2014 Dec 1;135(11):2612-22
references.pmid: 24740596
references.citation: J Pathol. 1999 Sep;189(1):12-9
references.pmid: 10451482
references.citation: Int J STD AIDS. 2008 Feb;19(2):106-11
references.pmid: 18334063
references.citation: Br J Cancer. 2006 Jul 3;95(1):96-101
references.pmid: 16773069
references.citation: Int J Cancer. 2012 Dec 15;131(12):2929-38
references.pmid: 22488743
references.citation: Gynecol Oncol. 2012 Dec;127(3):440-50
references.pmid: 22940493
references.citation: J Clin Microbiol. 2002 Mar;40(3):979-83
references.pmid: 11880426
references.citation: Am Fam Physician. 2003 Nov 15;68(10):1992-8
references.pmid: 14655809
references.citation: Zhonghua Liu Xing Bing Xue Za Zhi. 2007 Oct;28(10):941-6
references.pmid: 18399135
references.citation: Virology. 1991 Sep;184(1):9-13
references.pmid: 1651607
references.citation: Br J Cancer. 2009 Nov 3;101(9):1635-40
references.pmid: 19862002
references.citation: Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2271-6
references.pmid: 15598792
references.citation: J Natl Cancer Inst. 2005 Jul 20;97(14):1072-9
references.pmid: 16030305
references.citation: Cancer Causes Control. 2009 Nov;20(9):1705-13
references.pmid: 19705288
references.citation: Chin J Cancer Res. 2011 Mar;23(1):25-32
references.pmid: 23467401
references.citation: Br J Cancer. 2005 Feb 14;92(3):601-6
references.pmid: 15668709
references.citation: Int J Cancer. 2012 Feb 1;130(3):641-52
references.pmid: 21387308
references.citation: J Med Virol. 2002 Jun;67(2):246-52
references.pmid: 11992586
references.citation: Hum Vaccin. 2008 Nov-Dec;4(6):425-34
references.pmid: 18948732
references.citation: Vaccine. 2008 Sep 2;26(37):4795-808
references.pmid: 18640170
references.citation: Int J Cancer. 2006 Dec 1;119(11):2713-5
references.pmid: 16929495
references.citation: Sex Transm Dis. 2003 Aug;30(8):593-9
references.pmid: 12897679
references.citation: Br J Cancer. 2002 Jul 29;87(3):324-33
references.pmid: 12177803